Is sarcopenia associated with an increased risk of all- cause mortality and functional disability? Exp Gerontol
Background—While a recent meta-analysis of observational studies reported a statistically significant association between sarcopenia and both all-cause mortality and functional decline, a recently developed inverse heterogeneity (IVhet) model has been shown to be more valid than the traditional random-effects model used. Objective—The objective of this short report was to use a previous meta-analysis to compare the two approaches. Methods—Aggregate data meta-analysis of prospective observational studies conducted in any setting. Men and women 60 years of age and older in which all-cause mortality (12 studies, 14,169 participants) or functional decline (6 studies, 8,561 participants) were assessed. Using the IVhet model, pooling of previous studies regarding the association between sarcopenia and all-cause mortality as well as functional decline. Absolute and relative differences between IVhet and random-effects results were also calculated as well as influence analysis with each study deleted once. Non-overlapping 95% confidence intervals (CI) for odds ratios (OR) were considered statistically significant. Results—Sarcopenia was associated with an increased risk for all-cause mortality (OR = 3.64, 95% CI = 2.94 to 4.51) and functional decline (OR = 2.58, 95% CI = 1.33 to 4.99). Compared to the random-effects model, the OR was slightly higher (0.04 or 1.1%) but with wider CI (0.16 or 11.3%) for all-cause mortality and 0.45 (14.9%) lower with a CI that was 0.34 (10.2%) wider for functional decline. With each study deleted from the model once, results remained statistically significant for both all-cause mortality and functional decline. Conclusion—These results provide additional and more accurate evidence in support of an association between sarcopenia and an increased risk for both all-cause mortality and functional decline.
Digital Commons Citation
Kelley, G A. and Kelley, K S., "Is sarcopenia associated with an increased risk of all- cause mortality and functional disability? Exp Gerontol" (2017). Clinical and Translational Science Institute. 653.